Inqo Investments Ltd - Group Results for the year ended 29 February 2024
Announcement provided by
Inqo Investments Limited · INQO30/08/2024 11:40
Inqo Investments Limited
Group Results for the year ended 29 February 2024
CHAIRMAN AND CHIEF EXECUTIVE'S STATEMENT
Inqo Investments Limited ("Inqo" or "the Group") is a South African based social impact company that invests in businesses that tackle poverty and environmental challenges in Sub-Saharan Africa.
COMMENTARY
The Group remains in a strong financial position with total assets of R214 million including cash and cash equivalents of R43.77 million and minimal debt.
The results for the year under review showed revenue of R20.6 million (2023: R11.7 million) with a loss after tax of R5.31 million (2023: Profit of R3.77 million). The Group incurred a loss during the current year, largely due to its Kuzuko subsidiary as the tourism sector in
Kuzuko completed the planting of 30 million spekboom plants on 5,185 hectares (~12,800 acres) of land during this financial year. The total cost of planting the spekboom on the reserve through the Reforest Action carbon credit contract was R118 million. This has not been recognised in the accounts because its long-term value has not been crystallised.
Like businesses around the world, the Group has been heavily impacted by the Covid-19 pandemic with reduced earnings and implementation of cost saving measures. The severity of the impact and corresponding speed of recovery has varied across investee companies. Despite the challenges being faced, the directors of the Company have assessed the Company and its subsidiaries and agree that the operating units will continue as a going concern.
Inqo had been given grant funding of
Subsequent to year-end, Inqo has formalised two of its CARE investments in
Pabidi Lodge Budongo Limited was formed in June 2023 and the company has a 51% equity stake in the business. The shareholders' agreement has been finalised. The lodge will be the only luxury accommodation offering sustainable ecotourism to guests within the Budongo Forest.
A company, Flybox Budongo (BSF) Farm Limited was registered in
We expect that these investments will be operational in the Q4 2024.
SHARE ISSUE
In April 2024, the company issued 1,854,646 new ordinary shares, raising gross capital of R 29,985,428. This includes the conversion of two credit loan notes of
FINANCIAL RESULTS
The audited financial results for the year ended 29 February 2024 are as follows:
|
February 2024 R'000 |
February 2023 R'000 |
Revenue |
20,611 |
11,730 |
(Loss) / Profit for the year |
(5,304) |
3,775 |
Earnings per share |
(0.36) |
0.27 |
|
|
|
Total Assets |
214,460 |
210,257 |
|
|
|
Unutilised Grant Funding |
32,847 |
35,067 |
Total Liabilities excl Unutilised Grant Funding |
29,995 |
18,268 |
|
|
|
Net Assets |
151,618 |
156,922 |
(Loss) / Profit from operating activities includes the following items |
||
Spekboom Credit Contract |
Nil |
9,090 |
Grant income |
1,697 |
Nil |
Depreciation |
(2,937) |
(3,791) |
Personnel Costs |
(5,386) |
(4,854) |
Directors' Fees and Salaries |
(1,610) |
(959) |
Listing Expenses |
(933) |
(761) |
Professional Fees |
(370) |
(594) |
Impairments of loans: Four One |
(1,921) |
(108) |
Fair value adjustment of the buffalo herd |
(1,811) |
1,030 |
A copy of this announcement and the full audited financial statements will be available on the Company's website at Inqo.co.za.
INVESTEE COMPANIES: FINANCIAL, ENVIRONMENTAL AND SOCIAL PERFORMANCE COMMENTARY
· Kuzuko Lodge (Pty) Ltd (
Kuzuko Lodge is a subsidiary entity that operates a five-star luxury game lodge in the Eastern Cape. Kuzuko combines job creation, conservation and transformation in an eco-tourism environment. Kuzuko has been creating sustainable jobs for 20 years.
Despite incurring a loss in the current year, Kuzuko has experienced a 51% increase in revenues and related occupancy levels. Kuzuko transitioned from a hotel management group to independent management, intensified its marketing efforts and implemented key personnel changes, new systems and new cost control measures. These strategic changes will position Kuzuko for a positive financial outlook in the coming years.
· Inqo Africa (Pty) Ltd (
· Spekboom Trading (Pty) Ltd (
The Kuzuko Thicket Restoration Project commenced in September 2022 after an agreement was reached with an international third party, Re'Forest Action, to finance the project through forward sold carbon credit rights. The project will restore damaged ecosystems, benefit poor communities through job creation and capture carbon from the atmosphere. At 31 December 2023, the planting project was successfully concluded having planted 30 million spekboom cuttings across 5,185 hectares. The total cost of planting these cuttings amounted to R118M. During the height of the project, 350 people were involved in the project of which 250 people were housed and fed on the property. Planters were trained not only on the skills required for the project but also life skills.
· Four One Financial Services Limited (
· Kentegra (
In terms of the unaudited management accounts, Kentegra realised a positive EBITDA in 2023 and revenue increased by 100% from 2022 to 2023. Kentegra employs 300 people and have contracted to 26,000 farmers. Two surveys were commissioned to measure the impact of the company on the contracted farms during the financial year. The studies revealed that:
o 60% of the farmers' main source of income was from pyrethrum.
o 60% of the farmers have commenced other income generating projects from the pyrethrum income.
o 96% of the farmers would recommend Kentegra to a friend.
· South Lake Medical Centre - SLMC (
SLMC's unaudited management accounts for 2023 reflect a positive EBITDA, 5% higher than 2022. Despite ongoing challenges regarding delays in the payments from the National Health Insurance, SLMC performed well against their KPIs year on year; most notably safe deliveries 217 (2022: 156); surgeries 205 (2022: 61); patient visits 98,719 (2022: 82,387) and community outreach 69,726 (2022: 44,505). Declines noted include antenatal care (ANC) to safe delivery of 39% and HIV program of 25%.
Through Pfizer, SLMC successfully implemented a cervical cancer screening and HPV vaccination project aimed at enabling access to 2,000 women. By January 2024, 83% of the target had been met. In addition, 20 healthcare workers had been trained, 9 clinics were operationalised, the program was integrated into SLMCs service delivery for sustainability and extensive collaboration with communities, health care clinics and government had taken place.
· Sanergy Incorporated (
Sanergy's Fresh Life toilets are now in
· Kuzuko Foundation Trust (
Kuzuko Private Game Reserve was founded with the expressed aim of creating jobs in an area of exceptionally high unemployment. Kuzuko Foundation Trust (KFT) was established to continue and further that social mission through environmental education, mentoring, youth empowerment, job preparedness training, supporting local schools and supporting our local communities.
The Kuzuko Foundation manages the 14,414 hectares, which makes up the Kuzuko Private Game Reserve. The land is managed for conservation with the aim of rewilding and restoring the land to its natural state, fostering the return of native flora and fauna and creating a self-sustaining ecosystem.
Additionally, the Kuzuko Foundation works actively in the surrounding communities to further Kuzuko's social goals through an environmental education program, a mentoring scheme, work preparedness training, support for local farm schools and developing and supporting positive community initiatives. Kuzuko Lodge and Inqo continue to support the important work of the Kuzuko Foundation Trust.
SUMMARY OF SOCIAL & ENVIRONMENTAL METRICS SINCE PROJECT COMMENCEMENT
· Kuzuko Lodge
o 35,617 acres (14,414 hectares) of former farmland restored and protected as a game reserve
o 70 km of game fencing erected
o 45 FTE staff at Kuzuko in standard housing with flush toilets, power, water and solar panels
o 120 fixed term jobs
o Conservation of 2 endangered species, 8 endangered species protected, 23 species introduced
o Re-wilded 18 adult cheetahs with diverse genetics to bolster the meta-population in southern
· Southlake Medical Centre
o 98,719 patient visits including 386 HIV patients receiving care and counselling, 5,599 people receiving health education including through community outreach, 217 safe deliveries, 205 surgeries, 2,000 cervical cancer screens and 700+ HPV vaccinations
· Kentegra
o 300 FTE and 26,000 contracted out-growers
· Sanergy
o 1,000 FTE, 2,000 indirect jobs, 5,000 toilets serving 270,000 people
· Spekboom Trading
o 5,185 hectares degraded land planted with 30 million spekboom; 350 fixed term jobs
STAFF
The directors would like to take this opportunity to thank all the operating staff in the Group for their contribution and commitment to the Group's objectives during this challenging time.
KS Tan
Chairman
Issued on: 30 August 2024
Enquiries
Inqo Investments Limited |
Tel: +44 7768 613346 |
Dr Kim Tan, Chairman |
Email: kimtan2@springhilluk.com |
|
|
Hobart Capital Markets LLP |
|
AQSE Corporate Adviser and Broker |
Tel: +44 (0)20 7070 5665 |
Dr Wang Chong |
Email: wang.chong@hobartcapital.com |
Condensed consolidated and separate Annual Financial Statements for the year ended 29 February 2024
Statements of Financial Position
|
Group |
Group |
Company |
Company |
|
|
Figures in R |
|
2024 |
2023 |
2024 |
2023 |
|
Assets Non-current assets |
|
|
|
|
|
|
Property, plant and equipment |
|
151,980,925 |
154,054,726 |
150,894,906 |
152,888,843 |
|
Right-of-use assets |
|
68,147 |
236,171 |
|
|
|
Intangible assets |
|
840 |
1,840 |
|
|
|
Investments in subsidiaries |
|
|
|
1,503 |
1,503 |
|
Trade and other receivables |
|
|
|
238,570 |
849,417 |
|
Other investments |
|
7,306,227 |
9,017,656 |
5,638,507 |
7,349,936 |
|
Loans to subsidiaries |
|
|
|
22,059,056 |
14,990,626 |
|
Total non-current assets |
|
159,356,139 |
163,310,393 |
178,832,542 |
176,080,325 |
|
Current assets |
|
|
|
|
|
|
Inventories |
|
4,295,937 |
4,862,236 |
3,702,582 |
4,194,454 |
|
Trade and other receivables |
|
6,059,424 |
3,124,989 |
4,306,972 |
1,710,486 |
|
Biological assets |
|
977,000 |
2,788,980 |
977,000 |
2,788,980 |
|
Cash and cash equivalents |
|
43,771,590 |
36,170,112 |
41,873,765 |
35,729,803 |
|
Total current assets |
|
55,103,951 |
46,946,317 |
50,860,319 |
44,423,723 |
|
Total assets |
|
214,460,090 |
210,256,710 |
229,692,861 |
220,504,048 |
|
|
Group |
Group |
Company |
Company |
|
|
Figures in R |
|
2024 |
2023 |
2024 |
2023 |
|
Equity and liabilities |
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
Ordinary share capital |
|
72,584,925 |
72,584,925 |
72,584,925 |
72,584,925 |
|
Share premium |
|
87,585,270 |
87,585,270 |
87,585,270 |
87,585,270 |
|
Accumulated loss |
|
(95,364,654) |
(90,101,796) |
(77,755,359) |
(72,960,353) |
|
Revaluation reserve |
|
86,693,347 |
86,693,347 |
86,693,347 |
86,693,347 |
|
Total equity attributable to owners of the parent |
|
151,498,888 |
156,761,746 |
169,108,183 |
173,903,189 |
|
Non-controlling interests |
|
119,507 |
160,218 |
|
|
|
Total equity |
|
151,618,395 |
156,921,964 |
169,108,183 |
173,903,189 |
|
Liabilities |
|
|
|
|
|
|
Non-current liabilities |
|
|
|
|
|
|
Deferred tax liabilities |
|
3,809,117 |
4,814,985 |
3,809,117 |
4,814,985 |
|
Loans from related parties |
|
3,423,672 |
4,511,589 |
3,423,672 |
4,363,278 |
|
Other loans |
|
18,931,500 |
|
18,931,500 |
|
|
Lease liabilities |
|
|
76,859 |
|
|
|
Total non-current liabilities |
|
26,164,289 |
9,403,433 |
26,164,289 |
9,178,263 |
|
Current liabilities |
|
|
|
|
|
|
Trade and other payables |
|
3,683,552 |
8,503,452 |
1,573,818 |
2,355,670 |
|
Lease liabilities |
|
80,155 |
214,080 |
|
|
|
Unutilised grant funding |
|
32,846,571 |
35,066,926 |
32,846,571 |
35,066,926 |
|
Bank overdraft |
|
67,128 |
146,855 |
|
|
|
Total current liabilities |
|
36,677,406 |
43,931,313 |
34,420,389 |
37,422,596 |
|
Total liabilities |
|
62,841,695 |
53,334,746 |
60,584,678 |
46,600,859 |
|
Total equity and liabilities |
|
214,460,090 |
210,256,710 |
229,692,861 |
220,504,048 |
|
Statements of Profit or Loss and Other Comprehensive Income
Group |
Group |
Company |
Company |
Figures in R 2024 |
2023 |
2024 |
2023 |
Revenue |
|
20,610,801 |
11,730,190 |
5,159,563 |
952,647 |
|
Cost of sales |
|
(2,421,823) |
(1,514,608) |
|
|
|
Gross profit |
|
18,188,978 |
10,215,582 |
5,159,563 |
952,647 |
|
Other income |
|
3,630,200 |
11,198,922 |
1,944,872 |
10,076,244 |
|
Personnel expenses |
|
(6,420,077) |
(5,813,170) |
(921,973) |
(905,084) |
|
Depreciation and amortisation |
|
(2,936,964) |
(3,790,520) |
(2,617,434) |
(3,395,008) |
|
Listing expenses |
|
(933,451) |
(760,765) |
(933,451) |
(760,765) |
|
Professional fees |
|
(945,650) |
(593,633) |
(945,650) |
(593,633) |
|
Bad debt |
|
|
(231,385) |
|
(231,385) |
|
Provision for doubtful debts |
|
(319,841) |
(286,490) |
(2,429,904) |
(1,286,490) |
|
Impairment and fair value adjustment |
|
(1,920,552) |
(107,993) |
(1,920,552) |
(1,584,875) |
|
Other expenses |
|
(12,836,487) |
(9,339,646) |
(2,236,734) |
(1,938,776) |
|
(Loss) / profit from operating activities |
|
(4,493,844) |
490,902 |
(4,901,263) |
332,875 |
|
Inventory write (down)/up |
|
(832,272) |
767,774 |
(832,272) |
767,774 |
|
Fair value adjustment |
|
(1,811,980) |
1,029,940 |
(1,811,980) |
1,029,940 |
|
Finance income |
|
995,676 |
506,642 |
1,807,315 |
1,087,555 |
|
Finance costs |
|
(167,020) |
(169,675) |
(62,675) |
(41,293) |
|
(Loss) / profit before tax |
|
(6,309,440) |
2,625,583 |
(5,800,875) |
3,176,851 |
|
Income tax credit |
|
1,005,869 |
1,149,324 |
1,005,869 |
1,149,324 |
|
(Loss) / profit for the year |
|
(5,303,571) |
3,774,907 |
(4,795,006) |
4,326,175 |
|
|
Group |
Group |
Company |
Company |
|
|
Figures in R |
|
2024 |
2023 |
2024 |
2023 |
|
(Loss) / profit for the year attributable to: |
|
|
|
|
|
|
Owners of Parent |
|
(5,262,858) |
3,862,532 |
(4,795,006) |
4,326,175 |
|
Non-controlling interest |
|
(40,713) |
(87,625) |
|
|
|
|
|
(5,303,571) |
3,774,907 |
(4,795,006) |
4,326,175 |
|
Earnings per share from continuing and discontinuing |
|
|
|
|
|
|
operations attributable to owners of the parent during |
|
|
|
|
|
|
the year |
|
|
|
|
|
|
Basic earnings per share |
|
|
|
|
|
|
Basic (loss)/ earnings per share |
|
(0.36) |
0.27 |
(0.33) |
0.30 |
|
Diluted earnings per share |
|
|
|
|
|
|
Diluted (loss)/ earnings per share |
|
(0.36) |
0.27 |
(0.33) |
0.30 |
|
Other comprehensive income net of tax |
|
|
|
|
|
|
Components of other comprehensive income that will not |
|
|
|
|
|
|
be reclassified to profit or loss |
|
|
|
|
|
|
Revaluation of land and buildings |
|
|
18,904,001 |
|
18,904,001 |
|
Deferred taxation |
|
|
(4,226,189) |
|
(4,226,189) |
|
Total other comprehensive income that will not be reclassified to profit or loss |
|
|
14,677,812 |
|
14,677,812 |
|
Total comprehensive income |
|
(5,303,571) |
18,452,719 |
(4,795,006) |
19,003,987 |
|
Comprehensive income attributable to: |
|
|
|
|
|
|
Comprehensive income, attributable to owners of parent |
|
(5,262,858) |
18,540,344 |
(4,795,006) |
19,003,987 |
|
Comprehensive income, attributable to non-controlling interests |
|
(40,713) |
(87,625) |
|
|
|
|
|
(5,303,571) |
18,452,719 |
(4,795,006) |
19,003,987 |
|
Statements of Cash Flows |
|
|||
|
Group |
Group |
Company |
Company |
Figures in R |
2024 |
2023 |
2024 |
2023 |
Net cash flows (used in)/ from operations |
(11,800,817) |
(1,449,746) |
(7,620,425) |
734,120 |
Interest paid |
(143,656) |
(169,674) |
(62,675) |
(41,293) |
Interest received |
995,676 |
506,642 |
952,982 |
504,453 |
Net cash flows (used in)/ from operating activities |
(10,948,797) |
(1,112,778) |
(6,730,118) |
1,197,280 |
Cash flows from/ (used in) investing activities |
|
|
|
|
Proceeds from sales of property, plant and equipment |
(17,103) |
|
(17,011) |
|
Purchase of property, plant and equipment |
(677,038) |
(269,388) |
(606,486) |
(200,904) |
Proceeds from sales of biological assets |
|
150,000 |
|
150,000 |
Increase in loans to subsidiary |
|
|
(6,214,097) |
(3,350,470) |
Loans (extended to)/repaid by other investments |
|
1,214,514 |
|
1,136,490 |
Grant funding received |
1,397,799 |
33,409,740 |
1,397,799 |
33,409,740 |
Cash flows from/ (used in) investing activities |
703,658 |
34,504,866 |
(5,439,795) |
31,144,856 |
Cash flows from financing activities |
|
|
|
|
Payments to related parties |
(1,087,917) |
|
(939,606) |
|
Loans received related parties |
17,786,900 |
2,839,253 |
17,786,900 |
2,818,616 |
Repayments of finance lease |
(234,148) |
(191,564) |
|
|
Cash flows from financing activities |
16,464,835 |
2,647,689 |
16,847,294 |
2,818,616 |
Net increase in cash and cash equivalents before effect of exchange rate changes |
6,219,696 |
36,039,777 |
4,677,381 |
35,160,752 |
Effect of exchange rate changes on cash and cash |
|
|
|
|
equivalents |
1,461,509 |
|
1,466,581 |
|
Net increase in cash and cash equivalents |
7,681,205 |
36,039,777 |
6,143,962 |
35,160,752 |
Cash and cash equivalents at beginning of the year |
36,023,257 |
(16,520) |
35,729,803 |
569,051 |
Cash and cash equivalents at end of the year |
43,704,462 |
36,023,257 |
41,873,765 |
35,729,803 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.